Lipid-lowering drug therapy in elderly patients

Current Pharmaceutical Design

Volumn 17, Issue 9, 2011, Pages 877-893

  Berthold, Heiner K ^a   Gouni Berthold, Ioanna ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Cardiovascular events; Cardiovascular risk; Coronary heart disease; Elderly patients; Geriatrics; Lipid lowering drugs; Statins; Stroke

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ATORVASTATIN; BEZAFIBRATE; C REACTIVE PROTEIN; CERIVASTATIN; CHOLESTEROL; CLOFIBRATE; COLESEVELAM; COLESTIPOL; COLESTYRAMINE; CONJUGATED ESTROGEN; CYCLOSPORIN; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GARLIC EXTRACT; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; NICOTINIC ACID; PITAVASTATIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; UNINDEXED DRUG; VERAPAMIL;

AGING; ALZHEIMER DISEASE; ANGINA PECTORIS; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CLINICAL DECISION MAKING; CLINICAL TRIAL; COMORBIDITY; DEMENTIA; DISEASE ASSOCIATION; DRUG SAFETY; DRUG WITHDRAWAL; DYSLIPIDEMIA; ECONOMIC ASPECT; GARLIC; GERIATRIC CARE; HEALTH CARE SYSTEM; HEART ATRIUM FIBRILLATION; HEART DEATH; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; ISCHEMIC HEART DISEASE; LIPID ANALYSIS; LIVER TOXICITY; MEDICAL DECISION MAKING; MEDICARE; MORTALITY; MYOPATHY; PRESCRIPTION; PRIORITY JOURNAL; QUALITY OF LIFE; RHABDOMYOLYSIS; RISK ASSESSMENT; RISK FACTOR; SECONDARY PREVENTION; STROKE; TRANSIENT ISCHEMIC ATTACK;

AGED; AGED, 80 AND OVER; CLINICAL TRIALS AS TOPIC; CORONARY DISEASE; DEMENTIA; FEMALE; GUIDELINES AS TOPIC; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; HYPOLIPIDEMIC AGENTS; MALE; PRIMARY PREVENTION; RISK FACTORS;

EID: 79958192032     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161211795428803     Document Type: Article

References (189)

1. Batchelor WB, Jollis JG, Friesinger GC. The challenge of healthcare delivery to the elderly patient with cardiovascular disease.Demographic, epidemiologic, fiscal, and health policy implications.Cardiol Clin 1999; 17: 1-15, vii.
2. United Nations: Programme on Ageing. Population Division, Department of Economic and Social Affairs, United NationsSecretariat. The Ageing of the World's Population. http://www.un.org/esa/socdev/ageing/popageing.html. 2011.
3. Williams MA, Fleg JL, Ades PA, et al. Secondary prevention ofcoronary heart disease in the elderly (with emphasis on patients >or =75 years of age): an American Heart Association scientificstatement from the Council on Clinical Cardiology Subcommitteeon Exercise, Cardiac Rehabilitation, and Prevention. Circulation 2002; 105: 1735-43.
4. Habenicht AJ, Salbach PB, Janssen-Timmen U, Ziegler R, Schettler G. [Pathophysiologic mechanisms of atherogenesis withspecial reference to lipid metabolism]. Internist (Berl) 1992; 33: 2-8.
5. Grundy SM. Age as a risk factor: you are as old as your arteries. Am J Cardiol 1999; 83: 1455-7, A7.
6. Gaw A. The care gap: underuse of statin therapy in the elderly. IntJ Clin Pract 2004; 58: 777-85.
7. DeWilde S, Carey IM, Bremner SA, Richards N, Hilton SR, Cook DG. Evolution of statin prescribing 1994-2001: a case of agism butnot of sexism? Heart 2003; 89: 417-21.
8. Ko DT, Mamdani M, Alter DA. Lipid-lowering therapy with statinsin high-risk elderly patients: the treatment-risk paradox. JAMA 2004; 291: 1864-70.
9. Berthold HK, Gouni-Berthold I, Bohm M, Krone W, BestehornKP. Patterns and predictors of statin prescription in patients withtype 2 diabetes. Cardiovasc Diabetol 2009; 8: 25.
10. Massing MW, Sueta CA, Chowdhury M, Biggs DP, Simpson RJ, Jr. Lipid management among coronary artery disease patients withdiabetes mellitus or advanced age. Am J Cardiol 2001; 87: 646-9,A10.
11. Pilote L, Beck CA, Karp I, et al. Secondary prevention after acutemyocardial infarction in four Canadian provinces, 1997-2000. CanJ Cardiol 2004; 20: 61-7.
12. Fonarow GC, French WJ, Parsons LS, Sun H, Malmgren JA. Useof lipid-lowering medications at discharge in patients with acutemyocardial infarction: data from the National Registry ofMyocardial Infarction 3. Circulation 2001; 103: 38-44.
13. Lemaitre RN, Furberg CD, Newman AB, et al. Time trends in theuse of cholesterol-lowering agents in older adults: theCardiovascular Health Study. Arch Intern Med 1998; 158: 1761-8.
14. Whincup PH, Emberson JR, Lennon L, Walker M, Papacosta O, Thomson A. Low prevalence of lipid lowering drug use in oldermen with established coronary heart disease. Heart 2002; 88: 25-9.
15. Majumdar SR, Gurwitz JH, Soumerai SB. Undertreatment ofhyperlipidemia in the secondary prevention of coronary arterydisease. J Gen Intern Med 1999; 14: 711-7.
16. Randomised trial of cholesterol lowering in 4444 patients withcoronary heart disease: the Scandinavian Simvastatin SurvivalStudy (4S). Lancet 1994; 344: 1383-9.
17. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatinon coronary events after myocardial infarction in patients withaverage cholesterol levels. Cholesterol and Recurrent Events Trialinvestigators. N Engl J Med 1996; 335: 1001-9.
18. Prevention of cardiovascular events and death with pravastatin inpatients with coronary heart disease and a broad range of initialcholesterol levels. The Long-Term Intervention with Pravastatin inIschaemic Disease (LIPID) Study Group. N Engl J Med 1998; 339:1349-57.
19. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heartdisease with pravastatin in men with hypercholesterolemia. West ofScotland Coronary Prevention Study Group. N Engl J Med 1995;333: 1301-7.
20. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acutecoronary events with lovastatin in men and women with averagecholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279:1615-22.
21. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety ofmore intensive lowering of LDL cholesterol: a meta-analysis ofdata from 170,000 participants in 26 randomised trials. Lancet 2010; 376: 1670-81.
22. Denke MA, Grundy SM. Hypercholesterolemia in elderly persons:resolving the treatment dilemma. Ann Intern Med 1990; 112: 780-92.
23. Benfante R, Reed D. Is elevated serum cholesterol level a riskfactor for coronary heart disease in the elderly? JAMA 1990; 263:393-6.
24. Rubin SM, Sidney S, Black DM, Browner WS, Hulley SB, Cummings SR. High blood cholesterol in elderly men and theexcess risk for coronary heart disease. Ann Intern Med 1990; 113:916-20.
25. Wong ND, Wilson PW, Kannel WB. Serum cholesterol as aprognostic factor after myocardial infarction: the Framingham Study. Ann Intern Med 1991; 115: 687-93.
26. Shipley MJ, Pocock SJ, Marmot MG. Does plasma cholesterolconcentration predict mortality from coronary heart disease inelderly people? 18 year follow up in Whitehall study. BMJ 1991;303: 89-92.
27. Weverling-Rijnsburger AW, Blauw GJ, Lagaay AM, Knook DL, Meinders AE, Westendorp RG. Total cholesterol and risk ofmortality in the oldest old. Lancet 1997; 350: 1119-23.
28. Schatz IJ, Masaki K, Yano K, Chen R, Rodriguez BL, Curb JD. Cholesterol and all-cause mortality in elderly people from theHonolulu Heart Program: a cohort study. Lancet 2001; 358: 351-5.
29. Welin L, Eriksson H, Larsson B, Svardsudd K, Tibblin G, Wilhelmsen L. Triglycerides and blood glucose are the majorcoronary risk factors in elderly Swedish men. The study of menborn in 1913. Ann Epidemiol 1992; 2: 113-9.
30. Simons LA, Simons J, Friedlander Y, McCallum J. Cholesterol andother lipids predict coronary heart disease and ischaemic stroke in the elderly, but only in those below 70 years. Atherosclerosis 2001;159: 201-8.
31. Jonsson A, Sigvaldason H, Sigfusson N. Total cholesterol andmortality after age 80 years. Lancet 1997; 350: 1778-9.
32. Corti MC, Guralnik JM, Salive ME, et al. HDL cholesterol predictscoronary heart disease mortality in older persons. JAMA 1995;274: 539-44.
33. Zimetbaum P, Frishman WH, Ooi WL, et al. Plasma lipids andlipoproteins and the incidence of cardiovascular disease in the veryelderly. The Bronx Aging Study. Arterioscler Thromb 1992; 12:416-23.
34. Aronow WS, Ahn C. Risk factors for new coronary events in alarge cohort of very elderly patients with and without coronary artery disease. Am J Cardiol 1996; 77: 864-6.
35. Reuben DB, Ix JH, Greendale GA, Seeman TE. The predictivevalue of combined hypoalbuminemia and hypocholesterolemia inhigh functioning community-dwelling older persons: MacArthurStudies of Successful Aging. J Am Geriatr Soc 1999; 47: 402-6.
36. Corti MC, Guralnik JM, Salive ME, et al. Clarifying the directrelation between total cholesterol levels and death from coronaryheart disease in older persons. Ann Intern Med 1997; 126: 753-60.
37. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative doseefficacy study of atorvastatin versus simvastatin, pravastatin,lovastatin, and fluvastatin in patients with hypercholesterolemia(the CURVES study). Am J Cardiol 1998; 81: 582-7.
38. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin,and pravastatin across doses (STELLAR Trial). Am J Cardiol 2003; 92: 152-60.
39. Guidelines for using serum cholesterol, high-density lipoproteincholesterol, and triglyceride levels as screening tests for preventingcoronary heart disease in adults. American College of Physicians. Part 1. Ann Intern Med 1996; 124: 515-7.
40. United States Preventive Services Task Force. Screening for lipiddisorders in adults: Recommendations and rationale: U.S.Preventive Services Task Force. The Internet Journal of Internal Medicine 2003; 3.
41. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recentclinical trials for the National Cholesterol Education Program AdultTreatment Panel III guidelines. Circulation 2004; 110: 227-39.
42. Executive Summary of The Third Report of The NationalCholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults(Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
43. D'Agostino RB, Sr., Vasan RS, Pencina MJ, et al. Generalcardiovascular risk profile for use in primary care: the FraminghamHeart Study. Circulation 2008; 117: 743-53.
44. Silventoinen K, Pankow J, Lindstrom J, Jousilahti P, Hu G, Tuomilehto J. The validity of the Finnish Diabetes Risk Score forthe prediction of the incidence of coronary heart disease and stroke,and total mortality. Eur J Cardiovasc Prev Rehabil 2005; 12: 451-8.
45. Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of globalcardiovascular risk in women: the Reynolds Risk Score. JAMA 2007; 297: 611-9.
46. D'Agostino RB, Sr., Grundy S, Sullivan LM, Wilson P. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 2001; 286: 180-7.
47. Brindle P, Beswick A, Fahey T, Ebrahim S. Accuracy and impactof risk assessment in the primary prevention of cardiovasculardisease: a systematic review. Heart 2006; 92: 1752-9.
48. Hense HW, Schulte H, Lowel H, Assmann G, Keil U. Framinghamrisk function overestimates risk of coronary heart disease in menand women from Germany--results from the MONICA Augsburgand the PROCAM cohorts. Eur Heart J 2003; 24: 937-45.
49. Liu J, Hong Y, D'Agostino RB, Sr., et al. Predictive value for theChinese population of the Framingham CHD risk assessment toolcompared with the Chinese Multi-Provincial Cohort Study. JAMA 2004; 291: 2591-9.
50. Marrugat J, D'Agostino R, Sullivan L, et al. An adaptation of the Framingham coronary heart disease risk function to European Mediterranean areas. J Epidemiol Community Health 2003; 57:634-8.
51. Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-yearfollow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation 2002; 105: 310-5.
52. Ferrario M, Chiodini P, Chambless LE, et al. Prediction ofcoronary events in a low incidence population. Assessing accuracyof the CUORE Cohort Study prediction equation. Int J Epidemiol 2005; 34: 413-21.
53. Zhang XF, Attia J, D'Este C, Yu XH, Wu XG. A risk scorepredicted coronary heart disease and stroke in a Chinese cohort. J Clin Epidemiol 2005; 58: 951-8.
54. U.K. Department of Health. Putting prevention first--vascularchecks: risk assessment and management. 2008.
55. Schauffler HH, D'Agostino RB, Kannel WB. Risk forcardiovascular disease in the elderly and associated Medicare costs:the Framingham Study. Am J Prev Med 1993; 9: 146-54.
56. Ridker PM, Rifai N, Clearfield M, et al. Measurement of Creactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001; 344:1959-65.
57. Grewal J, Chan S, Frohlich J, Mancini GB. Assessment of novel risk factors in patients at low risk for cardiovascular events basedon Framingham risk stratification. Clin Invest Med 2003; 26: 158-65.
58. Ali R, Alexander KP. Statins for the primary prevention of cardiovascular events in older adults: a review of the evidence. Am J Geriatr Pharmacother 2007; 5: 52-63.
59. Graham I, Atar D, Borch-Johnsen K, et al. European guidelines oncardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and byinvited experts). Eur J Cardiovasc Prev Rehabil 2007; 14 Suppl 2:S1-113.
60. NHS-National Institute for Health and Clinical Excellence. NICE clinical guideline Lipid modification - Cardiovascular riskassessment an the modification of blood lipids for the primary andsecondary prevention of cardiovascular disease; May 2008(reissued March 2010). www.nice.org.uk 2010.
61. NHS-National Institute for Health and Clinical Excellence. NICE clinical guideline Statins for the preventon of cardiovscularevents; January 2006 (Review date November 2008); TechnologyAppraisal 94. www.nice.org.uk 2008.
62. Lemaitre RN, Psaty BM, Heckbert SR, Kronmal RA, Newman AB, Burke GL. Therapy with hydroxymethylglutaryl coenzyme areductase inhibitors (statins) and associated risk of incidentcardiovascular events in older adults: evidence from the Cardiovascular Health Study. Arch Intern Med 2002; 162: 1395-400.
63. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2diabetes in the Collaborative Atorvastatin Diabetes Study(CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685-96.
64. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary andstroke events with atorvastatin in hypertensive patients who haveaverage or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149-58.
65. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin toprevent vascular events in men and women with elevated C-reactiveprotein. N Engl J Med 2008; 359: 2195-207.
66. Glynn RJ, Koenig W, Nordestgaard BG, Shepherd J, Ridker PM. Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial. Ann Intern Med 2010; 152: 488-96, W174.
67. de Lorgeril M, Salen P, Abramson J, et al. Cholesterol lowering, cardiovascular diseases, and the rosuvastatin-JUPITER controversy: a critical reappraisal. Arch Intern Med 2010; 170:1032-6.
68. Miettinen TA, Pyorala K, Olsson AG, et al. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian SimvastatinSurvival Study (4S). Circulation 1997; 96: 4211-8.
69. Lewis SJ, Moye LA, Sacks FM, et al. Effect of pravastatin on cardiovascular events in older patients with myocardial infarctionand cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial. Ann Intern Med 1998; 129: 681-9.
70. Hunt D, Young P, Simes J, et al. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronaryheart disease are equal to or exceed those seen in younger patients: Results from the LIPID trial. Ann Intern Med 2001; 134: 931-40.
71. Collins R, Heart Protection Study Collaborative Group. MRC/BHFHeart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
72. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomisedcontrolled trial. Lancet 2002; 360: 1623-30.
73. Afilalo J, Duque G, Steele R, Jukema JW, de Craen AJ, Eisenberg MJ. Statins for secondary prevention in elderly patients: ahierarchical bayesian meta-analysis. J Am Coll Cardiol 2008; 51:37-45.
74. Korn A, Blue Cross and Blue Shield Association Medical Advisory Panel. Special report: The Efficacy and Safety of Statins in the Elderly. Technology Evaluation Center (TEC), published incooperation with Kaiser Foundation Health Plan and SouthernCalifornia Permanente Medical Group; 2007.
75. Diamond GA, Kaul S. Prevention and treatment: a tale of two strategies. J Am Coll Cardiol 2008; 51: 46-8.
76. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-78.
77. Roberts CG, Guallar E, Rodriguez A. Efficacy and safety of statin monotherapy in older adults: a meta-analysis. J Gerontol A Biol SciMed Sci 2007; 62: 879-87.
78. Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Prospective studiescollaboration. Lancet 1995; 346: 1647-53.
79. Lewington S, Whitlock G, Clarke R, et al. Blood cholesterol andvascular mortality by age, sex, and blood pressure: a meta-analysisof individual data from 61 prospective studies with 55,000 vasculardeaths. Lancet 2007; 370: 1829-39.
80. Blood pressure, cholesterol, and stroke in eastern Asia. EasternStroke and Coronary Heart Disease Collaborative Research Group.Lancet 1998; 352: 1801-7.
81. Warshafsky S, Packard D, Marks SJ, et al. Efficacy of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors for prevention ofstroke. J Gen Intern Med 1999; 14: 763-74.
82. Vergouwen MD, de Haan RJ, Vermeulen M, Roos YB. Statintreatment and the occurrence of hemorrhagic stroke in patients witha history of cerebrovascular disease. Stroke 2008; 39: 497-502.
83. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003; 326: 1423.
84. Atkins D, Psaty BM, Koepsell TD, Longstreth WT, Jr., Larson EB.Cholesterol reduction and the risk for stroke in men. A meta-analysis of randomized, controlled trials. Ann Intern Med 1993;119: 136-45.
85. Hebert PR, Gaziano JM, Hennekens CH. An overview of trials of cholesterol lowering and risk of stroke. Arch Intern Med 1995;155: 50-5.
86. Briel M, Studer M, Glass TR, Bucher HC. Effects of statins on stroke prevention in patients with and without coronary heart disease: a meta-analysis of randomized controlled trials. Am J Med 2004; 117: 596-606.
87. Blauw GJ, Lagaay AM, Smelt AH, Westendorp RG. Stroke,statins, and cholesterol. A meta-analysis of randomized, placebocontrolled,double-blind trials with HMG-CoA reductase inhibitors. Stroke 1997; 28: 946-50.
88. Bucher HC, Griffith LE, Guyatt GH. Effect of HMGcoA reductase inhibitors on stroke. A meta-analysis of randomized, controlledtrials. Ann Intern Med 1998; 128: 89-95.
89. Byington RP, Davis BR, Plehn JF, et al. Reduction of stroke eventswith pravastatin: the Prospective Pravastatin Pooling (PPP) Project. Circulation 2001; 103: 387-92.
90. Crouse JR, III, Byington RP, Hoen HM, Furberg CD. Reductase inhibitor monotherapy and stroke prevention. Arch Intern Med 1997; 157: 1305-10.
91. Di MR, Marchioli R, Tognoni G. Cholesterol reduction and stroke occurrence: an overview of randomized clinical trials. Cerebrovasc Dis 2000; 10: 85-92.
92. Hebert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA 1997; 278: 313-21.
93. Henyan NN, Riche DM, East HE, Gann PN. Impact of statins on risk of stroke: a meta-analysis. Ann Pharmacother 2007; 41: 1937-45.
94. Belloto RJ, Jr. On statins, strokes, meta-analyses, competing risks,and the onward march of science. Ann Pharmacother 2007; 41:2055-7.
95. Manktelow BN, Potter JF. Interventions in the management of serum lipids for preventing stroke recurrence. Cochrane Database Syst Rev 2009; CD002091.
96. Amarenco P, Bogousslavsky J, Callahan A, III, et al. High-doseatorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355: 549-59.
97. Bushnell CD, Colon-Emeric CS. Secondary stroke preventionstrategies for the oldest patients: possibilities and challenges. Drugs Aging 2009; 26: 209-30.
98. Sanossian N, Ovbiagele B. Prevention and management of stroke in very elderly patients. Lancet Neurol 2009; 8: 1031-41.
99. Birjmohun RS, Hutten BA, Kastelein JJ, Stroes ES. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J Am Coll Cardiol 2005; 45: 185-97.
100. McKenney J. New perspectives on the use of niacin in thetreatment of lipid disorders. Arch Intern Med 2004; 164: 697-705.
101. Shepherd J, Betteridge J, Van GL. Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: a position paper developed by a European Consensus Panel. Curr Med Res Opin 2005; 21: 665-82.
102. Taylor AJ, Villines TC, Stanek EJ, et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 2009;361: 2113-22.
103. European Medicines Agency, Pharmacovigilance Working Party(PhVWP). PhVWP Assessment Report on the benefit: risk offibrates. Available online at http://www.bfarm.de/cae/servlet/contentblob/1019926/publicationFile/7941 5/fibrate-ar.pdf. 2010.
104. Backes JM, Gibson CA, Ruisinger JF, Moriarty PM. Fibrates: what have we learned in the past 40 years? Pharmacotherapy 2007; 27:412-24.
105. The Lipid Research Clinics Coronary Primary Prevention Trialresults. I. Reduction in incidence of coronary heart disease. JAMA 1984; 251: 351-64.
106. Bays HE, Goldberg RB. The 'forgotten' bile acid sequestrants: isnow a good time to remember? Am J Ther 2007; 14: 567-80.
107. Brunetti L, Hermes-Desantis ER. The role of colesevelamhydrochloride in hypercholesterolemia and type 2 diabetes mellitus. Ann Pharmacother 2010; 44: 1196-206.
108. Gagne C, Gaudet D, Bruckert E. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation 2002; 105:2469-75.
109. Berneis K, Rizzo M, Berthold HK, Spinas GA, Krone W, Gouni-Berthold I. Ezetimibe alone or in combination with simvastatinincreases small dense low-density lipoproteins in healthy men: a randomized trial. Eur Heart J 2010; 31: 1633-9.
110. Lipka L, Sager P, Strony J, Yang B, Suresh R, Veltri E. Efficacy and safety of coadministration of ezetimibe and statins in elderly patients with primary hypercholesterolaemia. Drugs Aging 2004;21: 1025-32.
111. Berthold HK, Sudhop T, von Bergmann K. Effect of a garlic oil preparation on serum lipoproteins and cholesterol metabolism: arandomized controlled trial. JAMA 1998; 279: 1900-2.
112. Berthold HK, Sudhop T. Garlic preparations for prevention of atherosclerosis. Curr Opin Lipidol 1998; 9: 565-9.
113. Gardner CD, Lawson LD, Block E, et al. Effect of raw garlic vs commercial garlic supplements on plasma lipid concentrations in adults with moderate hypercholesterolemia: a randomized clinical trial. Arch Intern Med 2007; 167: 346-53.
114. Berthold HK, Unverdorben S, Degenhardt R, Bulitta M, Gouni-Berthold I. Effect of policosanol on lipid levels among patients with hypercholesterolemia or combined hyperlipidemia: a randomized controlled trial. JAMA 2006; 295: 2262-9.
115. Gouni-Berthold I, Berthold HK. Policosanol: clinical pharmacology and therapeutic significance of a new lipid-loweringagent. Am Heart J 2002; 143: 356-65.
116. Marinangeli CP, Jones PJ, Kassis AN, Eskin MN. Policosanols as nutraceuticals: fact or fiction. Crit Rev Food Sci Nutr 2010; 50:259-67.
117. Dulin MF, Hatcher LF, Sasser HC, Barringer TA. Policosanol is ineffective in the treatment of hypercholesterolemia: a randomized controlled trial. Am J Clin Nutr 2006; 84: 1543-8.
118. Kamal-Bahl SJ, Burke T, Watson D, Wentworth C.Discontinuation of lipid modifying drugs among commercially insured United States patients in recent clinical practice. Am J Cardiol 2007; 99: 530-4.
119. Eaton CB, Lapane KL, Murphy JB, Hume AL. Effect of statin (HMG-Co-A-Reductase Inhibitor) use on 1-year mortality and hospitalization rates in older patients with cardiovascular disease living in nursing homes. J Am Geriatr Soc 2002; 50: 1389-95.
120. Foody JM, Rathore SS, Galusha D, et al. Hydroxymethylglutaryl-CoA reductase inhibitors in older persons with acute myocardial infarction: evidence for an age-statin interaction. J Am Geriatr Soc 2006; 54: 421-30.
121. Armitage J. The safety of statins in clinical practice. Lancet 2007;370: 1781-90.
122. Santanello NC, Barber BL, Applegate WB, et al. Effect of pharmacologic lipid lowering on health-related quality of life in older persons: results from the Cholesterol Reduction in Seniors Program (CRISP) Pilot Study. J Am Geriatr Soc 1997; 45: 8-14.
123. Dale KM, Coleman CI, Henyan NN, Kluger J, White CM. Statinsand cancer risk: a meta-analysis. JAMA 2006; 295: 74-80.
124. Bonovas S, Filioussi K, Tsavaris N, Sitaras NM. Statins and cancerrisk: a literature-based meta-analysis and meta-regression analysisof 35 randomized controlled trials. J Clin Oncol 2006; 24: 4808-17.
125. LaRosa JC, Applegate W, Crouse JR, III, et al. Cholesterol lowering in the elderly. Results of the Cholesterol Reduction in Seniors Program (CRISP) pilot study. Arch Intern Med 1994; 154:529-39.
126. Silva MA, Swanson AC, Gandhi PJ, Tataronis GR. Statin-relatedadverse events: a meta-analysis. Clin Ther 2006; 28: 26-35.
127. Kashani A, Phillips CO, Foody JM, et al. Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation 2006; 114: 2788-97.
128. Pasternak RC, Smith SC, Jr., Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC/AHA/NHLBI clinical advisory on theuse and safety of statins. J Am Coll Cardiol 2002; 40: 567-72.
129. Chatzizisis YS, Koskinas KC, Misirli G, Vaklavas C, HatzitoliosA, Giannoglou GD. Risk factors and drug interactions predisposingto statin-induced myopathy: implications for risk assessment,prevention and treatment. Drug Saf 2010; 33: 171-87.
130. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy.JAMA 2003; 289: 1681-90.
131. Joy TR, Hegele RA. Narrative review: statin-related myopathy. Ann Intern Med 2009; 150: 858-68.
132. Athyros VG, Tziomalos K, Gossios TD, et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patientswith coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 2010; 376: 1916-22.
133. Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary preventionafter myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005; 294: 2437-45.
134. Deedwania P, Stone PH, Bairey Merz CN, et al. Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE). Circulation 2007;115: 700-7.
135. Shepherd J. Preventing the next event in the elderly: the PROSPERperspective. Atheroscler Suppl 2003; 4: 17-22.
136. Bottorff MB. Statin safety: what to know. Am J Geriatr Cardiol 2004; 13: 34-8.
137. Kester MI, Scheltens P. Dementia: the bare essentials. Pract Neurol 2009; 9: 241-51.
138. Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med 2010; 362: 329-44.
139. Kirshner HS. Vascular dementia: a review of recent evidence for prevention and treatment. Curr Neurol Neurosci Rep 2009; 9: 437-42.
140. Panza F, D'Introno A, Colacicco AM, et al. Cognitive frailty: Predementia syndrome and vascular risk factors. Neurobiol Aging 2006; 27: 933-40.
141. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet 2000; 356: 1627-31.
142. Rockwood K, Kirkland S, Hogan DB, et al. Use of lipid-lowering agents, indication bias, and the risk of dementia in communitydwellingelderly people. Arch Neurol 2002; 59: 223-7.
143. Bettermann K, Arnold AM, Williamson J, et al. Statins, Risk of Dementia, and Cognitive Function: Secondary Analysis of the Ginkgo Evaluation of Memory Study. J Stroke Cerebrovasc Dis 2011.
144. Glasser SP, Wadley V, Judd S, et al. The association of statin useand statin type and cognitive performance: analysis of the reasonsfor geographic and racial differences in stroke (REGARDS) study.Clin Cardiol 2010; 33: 280-8.
145. Haag MD, Hofman A, Koudstaal PJ, Stricker BH, Breteler MM. Statins are associated with a reduced risk of Alzheimer diseaseregardless of lipophilicity. The Rotterdam Study. J NeurolNeurosurg Psychiatry 2009; 80: 13-7.
146. Feldman HH, Doody RS, Kivipelto M, et al. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology 2010; 74: 956-64.
147. Sparks DL, Connor DJ, Sabbagh MN, Petersen RB, Lopez J,Browne P. Circulating cholesterol levels, apolipoprotein Egenotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: results of the Alzheimer's Disease Cholesterol-Lowering Treatment (ADCLT) trial. Acta Neurol Scand Suppl 2006; 185: 3-7.
148. Simons M, Schwarzler F, Lutjohann D, et al. Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26-week randomized, placebo-controlled, double-blindtrial. Ann Neurol 2002; 52: 346-50.
149. McGuinness B, O'Hare J, Craig D, Bullock R, Malouf R, Passmore P. Statins for the treatment of dementia. Cochrane Database SystRev 2010; CD007514.
150. Tatley M, Savage R. Psychiatric adverse reactions with statins, fibrates and ezetimibe: implications for the use of lipid-loweringagents. Drug Saf 2007; 30: 195-201.
151. Sparks L. Statins and cognitive function. J Neurol Neurosurg Psychiatry 2009; 80: 1-2.
152. Sano M. Multi-center, randomized, double-blind, placebo-controlledtrial of simvastatin to slow the progression ofAlzheimer's disease. ICAD abstracts 2008.
153. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 1999; 282: 2340-6.
154. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins onlow density lipoprotein cholesterol, ischaemic heart disease, andstroke: systematic review and meta-analysis. BMJ 2003; 326: 1-7.
155. Pignone M, Phillips C, Mulrow C. Use of lipid lowering drugs forprimary prevention of coronary heart disease: meta-analysis ofrandomised trials. BMJ 2000; 321: 983-6.
156. Bartlett C, Davey P, Dieppe P, Doyal L, Ebrahim S, Egger M. Women, older persons, and ethnic minorities: factors associated with their inclusion in randomised trials of statins 1990 to 2001.Heart 2003; 89: 327-8.
157. Cheung BM, Lauder IJ, Lau CP, Kumana CR. Meta-analysis oflarge randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes. Br J Clin Pharmacol 2004; 57: 640-51.
158. Ebrahim S, Davey SG, McCabe C, et al. What role for statins? Areview and economic model. Health Technol Assess 1999; 3: i-91.
159. Katerndahl DA, Lawler WR. Variability in meta-analytic results concerning the value of cholesterol reduction in coronary heart disease: a meta-meta-analysis. Am J Epidemiol 1999; 149: 429-41.
160. Thavendiranathan P, Bagai A, Brookhart MA, Choudhry NK.Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials. Arch Intern Med 2006; 166: 2307-13.
161. Ward S, Lloyd JM, Pandor A, et al. A systematic review andeconomic evaluation of statins for the prevention of coronaryevents. Health Technol Assess 2007; 11: 1-iv.
162. Wilt TJ, Bloomfield HE, MacDonald R, et al. Effectiveness of statin therapy in adults with coronary heart disease. Arch Intern Med 2004; 164: 1427-36.
163. Aronow WS. Should the NCEP III guidelines be changed in elderly and younger persons at high risk for cardiovascular events? J Gerontol A Biol Sci Med Sci 2005; 60: 591-2.
164. Gransbo K, Melander O, Wallentin L, et al. Cardiovascular and cancer mortality in very elderly post-myocardial infarction patients receiving statin treatment. J Am Coll Cardiol 2010; 55: 1362-9.
165. Taylor F, Ward K, Moore TH, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2011; 1: CD004816.
166. Major outcomes in moderately hypercholesterolemic, hypertensivepatients randomized to pravastatin vs usual care: TheAntihypertensive and Lipid-Lowering Treatment to Prevent HeartAttack Trial (ALLHAT-LLT). JAMA 2002; 288: 2998-3007.
167. Brugts JJ, Yetgin T, Hoeks SE, et al. The benefits of statins inpeople without established cardiovascular disease but withcardiovascular risk
168. Ray KK, Seshasai SR, Erqou S, et al. Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. ArchIntern Med 2010; 170: 1024-31.
169. Strandberg TE, Pitkala K, Berglind S, Nieminen MS, Tilvis RS.Multifactorial cardiovascular disease prevention in patients aged 75 years and older: A randomized controlled trial: Drugs and Evidence Based Medicine in the Elderly (DEBATE) Study. Am Heart J 2001; 142: 945-51.
170. Strandberg TE, Pitkala KH, Tilvis RS. Statin treatment is associated with clearly reduced mortality risk of cardiovascular patients aged 75 years and older. J Gerontol A Biol Sci Med Sci 2008; 63: 213-4.
171. Genest J, McPherson R, Frohlich J, et al. 2009 CanadianCardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. Can J Cardiol 2009; 25: 567-79.
172. Cooper A, O'Flynn N. Risk assessment and lipid modification for primary and secondary prevention of cardiovascular disease: summary of NICE guidance. BMJ 2008; 336: 1246-8.
173. JBS 2: Joint British Societies' guidelines on prevention ofcardiovascular disease in clinical practice. Heart 2005; 91 Suppl 5:v1-52.
174. NHS-National Institute for Health and Clinical Excellence. NICEclinical guideline Lipid modification - Cardiovascular riskassessment an the modification of blood lipids for the primary andsecondary prevention of cardiovascular disease; May 2008(reissued March 2010). www.nice.org.uk 2010.
175. Allen Maycock CA, Muhlestein JB, Horne BD, et al. Statin therapy is associated with reduced mortality across all age groups of individuals with significant coronary disease, including very elderly patients. J Am Coll Cardiol 2002; 40: 1777-85.
176. Grundy SM, Cleeman JI, Rifkind BM, Kuller LH. Cholesterollowering in the elderly population. Coordinating Committee of theNational Cholesterol Education Program. Arch Intern Med 1999;159: 1670-8.
177. Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. The effect ofstatins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greekatorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol 2004; 57: 728-34.
178. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid loweringwith atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352: 1425-35.
179. Shepherd J, Kastelein JJ, Bittner V, et al. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study.Clin J Am Soc Nephrol 2007; 2: 1131-9.
180. Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on theprogression of renal disease: a meta-analysis. Kidney Int 2001; 59:260-9.
181. Alter DA, Manuel DG, Gunraj N, Anderson G, Naylor CD,Laupacis A. Age, risk-benefit trade-offs, and the projected effects of evidence-based therapies. Am J Med 2004; 116: 540-5.
182. Mendes de Leon CF, Bang W, Bienias JL, Glass TA, Vaccarino V, Kasl SV. Changes in disability before and after myocardial infarction in older adults. Arch Intern Med 2005; 165: 763-8.
183. van Jaarsveld CH, Sanderman R, Miedema I, Ranchor AV, Kempen GI. Changes in health-related quality of life in older patients with acute myocardial infarction or congestive heart failure: a prospective study. J Am Geriatr Soc 2001; 49: 1052-8.
184. Fried LP, Tangen CM, Walston J, et al. Frailty in older adults:evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001; 56:M146-M156.
185. Alexander KP, Newby LK, Cannon CP, et al. Acute coronary care in the elderly, part I: Non-ST-segment-elevation acute coronary syndromes: a scientific statement for healthcare professionals fromthe American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology. Circulation 2007; 115: 2549-69.
186. Holmes HM, Hayley DC, Alexander GC, Sachs GA. Reconsideringmedication appropriateness for patients late in life. Arch InternMed 2006; 166: 605-9.
187. Wilson MM. Aronow's Should the NCEP III guidelines bechanged in elderly and younger persons at high risk forcardiovascular events? Cholesterol and the aged:.and the beatgoes on. J Gerontol A Biol Sci Med Sci 2005; 60: 600-2.
188. Fried TR, Tinetti ME, Iannone L. Primary care clinicians' experiences with treatment decision making for older persons withmultiple conditions. Arch Intern Med 2011; 171: 75-80.
189. Mangoni AA, Jackson SH. The implications of a growing evidencebase for drug use in elderly patients. Part 1. Statins for primary andsecondary cardiovascular prevention. Br J Clin Pharmacol 2006;61: 494-501.